This is a new technology intended to enhance organ and tissue preservation prior to transplantation. It does have a significant impact in both the morbidity and the mortality currently experienced by transplant candidates and organ transplant recipients . This new technology provides effective ex-vivo oxygenation. for organs and tissues.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
FIGURES OF MERIT
Value Proposition: This technology has the capability to improve the current standards for organ preservation by providing effective ex-vivo oxygenation. This would allow us to extend the use of expanded criteria organs, which are currently discarded at an unprecedented rate (>50%). This should allow a decrease on waiting times for organ transplantation, while decreasing the morbidity, mortality and the costs for the patients on the waiting list. Improved organ function should decrease the length-of-stay and overall costs of the recipient population. This should also have a positive impact on organ acquisition costs by promoting a significant increase in organ utilization. The overall cost of the transplant therapy should decrease if the long term if the results (patient and graft survival) can be improved.
Organ preservation is currently based on cold storage (CS), where the organs remain hypothermic and anoxic for a limited period of time. CS has a direct negative impact in the time and the distances imposed by the current system of organ allocation.
Machine perfusion is already a clinical reality in kidney and lung transplantation, but extremely costly with the new devices used under normothermic (37°C) conditions and without the use of oxygen carrier solutions.
Organization Type: Early-stage Startup (Seed)
GOVT/EXTERNAL FUNDING SOURCES
Vetted Programs/Awards: 1. Charitable foundation (completed) - $1,000,000
2. PA state grant (completed) - $35,6999
3. Department of Defense (DOD) - $500,000 (completed)
4. DOD (current) - $1,000,000
5. DOD (current) - $600,000
6. UPMC Internal grant - $450,000
7. Corporate Research Agreement (industry) - $1,600,000
External Funding to Date: 1. Charitable foundation (completed) - $1,000,000
2. Corporate Research Agreement (Virtech Bio LLC, startup company) - $1,600,000
3. UPMC Internal grant - $450,000